Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.33 USD | -1.40% | -1.73% | -14.61% |
27/06 | Wells Fargo Adjusts BioMarin Pharmaceutical Price Target to $115 From $110, Maintains Overweight Rating | MT |
24/06 | BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P 1000 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.61% | 15.63B | |
+2.99% | 95.18B | |
-4.34% | 37.55B | |
-10.41% | 33.75B | |
+75.79% | 28.2B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B | |
+6.22% | 9.09B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc., Prosensa Holding N.V. - M&A Call